Recruiting

8F BASHIR™ & r-tPA

Sponsor:

Thrombolex, Inc.

Code:

NCT06433011

Conditions

Pulmonary Embolism

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

The Bashir™ Endovascular Catheter

r-tPA

Study Details

Brief summary:

To demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).

Conditions

Pulmonary Embolism

Study ID

NCT06433011

Start date

Oct 17, 2024

Status verified date

Jul, 2026

Completion date

Apr 25, 2028

Anticipated

Primary completion date

Apr 25, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria

1. Willing and able to provide informed consent;
2. PE symptom duration ≤ 15 days;
3. Filling defect in at least one major lobar pulmonary artery as determined by CTA;
4. Patient is diagnosed with intermediate risk PE;
5. RV/LV diameter ratio ≥ 0.9 by CTA, as determined by investigative site;
6. Willing and able to comply with all study procedures and 7-day and 30-day telephone follow-up visit.

Exclusion Criteria:

1. Previous history of stroke with residual hemiplegia;
2. Major surgery ≤ 10 days prior to inclusion in the study;
3. Platelet count < 100,000/μL;
4. Pulmonary thrombectomy within the previous 4 days;
5. Uncontrolled hypertension defined as systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg at the time of the procedure;
6. Administration of thrombolytic agents within the previous 4 days;
7. Absolute contraindication to anticoagulation;
8. Clinician deems high-risk for catastrophic bleeding;
9. Pregnancy;
10. Any vasopressor or inotropic support;
11. Cardiac arrest (including pulseless electrical activity (PEA) and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and/or referring institution;
12. Planning to administer r-tPA by infusion after the r-tPA is administered by pulse sprays;
13. Currently participating in another study;
14. In the opinion of the investigator, the subject is not a suitable candidate for the study.

Study Design

Enrollment

500 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: BEC Treatment

The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.

Interventions

The Bashir™ Endovascular Catheter

The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.

r-tPA

Pulse spray and infusion

Primary outcome measure

  • Efficacy: Death from any cause or hemodynamic decompensation (or collapse) [ Time Frame: Procedure through 7-day follow-up ]

Central Contacts and Locations

Central contacts

Locations

Honor Health

Recruiting

Scottsdale, Arizona, United States, 85258

Contacts

Chintan Patel

480-323-1046

Carondelet St. Joseph's Hospital

Recruiting

Tuscon, Arizona, United States, 85711

Contacts

Sundeep Shenoy

520-873-1591

Radiology and Imaging Specialists

Recruiting

Lakeland, Florida, United States, 33801

Contacts

Kurt Gordon

"863-688-2334

Emory University

Recruiting

Atlanta, Georgia, United States, 30308

Contacts

Pratik Sandesara

404-686-7468

Rush University Medical Center

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Bulent Arslan

434-242-8364

Profound Research

Recruiting

Hobart, Indiana, United States, 46342

Community Health

Recruiting

Indianapolis, Indiana, United States, 46256

Contacts

Michael Robertson

317-621-7724

Boston Medical Center

Recruiting

Boston, Massachusetts, United States, 02135

Contacts

Tariq Bhat

617-779-6731

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02481

Contacts

Jeffrey Weinstein

617-754-2523

Lahey Hospital & Medical Center

Recruiting

Burlington, Massachusetts, United States, 01805

Contacts

Michael Levy

781-744-8460

North Mississippi Medical Center

Recruiting

Tupelo, Mississippi, United States, 38801

Contacts

Barry Bertolet

662-213-0405

Dartmouth Hitchcock

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

Michael Young

615-927-9043

Cooper Health

Recruiting

Camden, New Jersey, United States, 08103

Contacts

Elias Iliadis

856-757-7832

St. Joseph's

Recruiting

Liverpool, New York, United States, 13088

Contacts

Ayman Iskander

315-234-4412

Northwell Health

Recruiting

Manhasset, New York, United States, 11030

Contacts

Vincent Gallo

718-226-6422

Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Jenanan Vairavamurthy

212-659-9151

TriHealth

Recruiting

Cincinnati, Ohio, United States, 45242

Contacts

Adam Reichard

513-865-9898

Miami Valley/Wright State University/Premier Health

Recruiting

Dayton, Ohio, United States, 45435

Contacts

Ryan Brandt

937-208-3689

Jobst Vascular Institute - ProMedica Hospital

Recruiting

Toledo, Ohio, United States, 43606

Contacts

Ahmad Younes

419-291-2111

Temple University

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Contacts

Parth Rali

215-707-1359

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Contacts

Alexander Sullivan

615-343-8647

Sentara

Recruiting

Norfolk, Virginia, United States, 23507

Contacts

David Dexter

757-395-1600

Charleston Area Medical Center

Recruiting

Charleston, West Virginia, United States, 25304

Contacts

Mohammad Eslami

304-388-5432

More Information

Sponsor

Thrombolex, Inc.

Last update posted

Jul 14, 2026

Last verified

Jul, 2026

Keywords

  • Pulmonary Embolism
  • Catheter Directed Therapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Thrombolex, Inc. on 2026-07-14.